SML2699
SHMT inhibitor Hit 1
≥98% (HPLC)
别名:
4,4′-[2,4-Pyrimidinediylbis(4,1-phenyleneimino)]bis[4-oxo-butanoic acid
InChI
1S/C24H22N4O6/c29-20(9-11-22(31)32)26-17-5-1-15(2-6-17)19-13-14-25-24(28-19)16-3-7-18(8-4-16)27-21(30)10-12-23(33)34/h1-8,13-14H,9-12H2,(H,26,29)(H,27,30)(H,31,32)(H,33,34)
InChI key
LZRQXDAEFLBXCL-UHFFFAOYSA-N
SMILES string
O=C(NC1=CC=C(C2=NC=CC(C3=CC=C(C=C3)NC(CCC(O)=O)=O)=N2)C=C1)CCC(O)=O
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
Inhibition of serine/glycine synthesis by SHMT inhibitors can be an effective strategy to treat serine/glycine synthesis-dependent cancers. Therefore, SHMT inhibitor can be a potential cancer drug target. SHMT inhibitor Hit 1 may inhibit SHMT with an IC50 of 0.53 μM.
SHMT inhibitor Hit 1 is a potent and specific inhibitor of serine hydroxymethyltransferase (SHMT). SHMT inhibitor Hit 1 potently inhibits SHMT1 and SHMT2 in rat liver homogenate.
potent and specific inhibitor of serine hydroxymethyltransferase (SHMT)
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Shauni Lien Geeraerts et al.
Molecular cancer therapeutics, 20(1), 50-63 (2020-11-19)
Metabolic rewiring is a hallmark of cancer that supports tumor growth, survival, and chemotherapy resistance. Although normal cells often rely on extracellular serine and glycine supply, a significant subset of cancers becomes addicted to intracellular serine/glycine synthesis, offering an attractive
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持